Tim Opler, Flame Biosciences co-CEO
January 11, 2023 12:48 PM ESTUpdated 05:25 PM
Startups
R&D

Flame Bio­sciences search­es for fu­ture af­ter No­var­tis flunks on canakinum­ab

Kyle LaHucik

Senior Reporter

Flame Bio­sciences de­buted with the idea that its mon­o­clon­al an­ti­body that in­hibits IL-1ß, a key cy­tokine in in­flam­ma­tion, would be ef­fec­tive at re­duc­ing can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times